VolitionRx (OTC:VNRX) with $6 Target Got Analyzed By Maxim Group.

May 17, 2018 - By Norman Soto

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 5.80, from 2017Q3’s 7. 3 investors sold all, 2 reduced holdings as VolitionRx Limited ratio dived. 4 increased stakes while 2 funds bought stakes. Funds hold 4.52 million shares thus 51.36% less from 2017Q3’s 9.30 million shares.

Morgan Stanley owns 63,400 shs. Vanguard Gp owns 204,994 shs. Bessemer Group holds 10,000 shs or 0% of its capital. Bancshares Of New York Mellon Corporation reported 10,335 shs stake. Creative Planning holds 13,200 shs. Northern Tru owns 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX) for 22,714 shs. Blackrock holds 0% or 11,219 shs. Lagoda Inv Management L P reported 3.94% in VolitionRx Limited (NYSEAMERICAN:VNRX). Moreover, Garrison Bradford Assoc has 0.04% invested in VolitionRx Limited (NYSEAMERICAN:VNRX) for 15,500 shs. Leisure Cap Mgmt accumulated 0.18% or 74,863 shs. Royal National Bank Of Canada has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Geode Cap Mgmt Limited Liability Company accumulated 0% or 100,890 shs. Knoll Management L P has invested 0.91% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Moreover, Bridgeway Cap Inc has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Brown Brothers Harriman & invested 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX).

What Price Target Has Maxim Group Given VolitionRx (OTC:VNRX)

After Maxim Group’s $6 target price was issued to clients and investors on Wednesday, 16 May, the firm initiated coverage of the VolitionRx (OTC:VNRX)‘s stock. The company set a “Buy” rating of VNRX.

Ticker’s shares touched $2.25 during the last trading session after 8.70% change.VolitionRx Limited has 145,762 shares volume, 3.92% up from normal. VNRX is downtrending and has moved 42.82% since May 17, 2017. VNRX underperformed by 54.37% the S&P 500.

VolitionRx Limited (NYSEAMERICAN:VNRX) is anticipated to announce earnings on August, 8., Zacks reports. Analysts predict $-0.17 EPS. That’s $0.04 down or 30.77 % from 2017’s earnings of $-0.13. Analysts at Wall Street see VolitionRx Limited’s 0.00 % EPS growth compared to $-0.17 EPS for previous quarter.

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide.The company has $67.57 million market cap. The firm develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Last it reported negative earnings.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: